← FDA DRUG APPROVALS
FDA ANDA · ANDA078104
NASAL ALLERGY
triamcinolone acetonide
Sponsor: PERRIGO PHARMA INTL
APPLICATION
ANDA078104
TYPE
ANDA
ORIGINAL APPROVAL
2009-07-30
LATEST ACTION
2020-11-12
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Discontinued, Over-the-counter
Products
TRIAMCINOLONE ACETONIDEDiscontinued
TRIAMCINOLONE ACETONIDE 0.055MG/SPRAY · SPRAY, METERED · NASAL
TRIAMCINOLONE ACETONIDEOver-the-counter
TRIAMCINOLONE ACETONIDE 0.055MG/SPRAY · SPRAY, METERED · NASAL
Approval history
2020-11-12Labeling · Supplement 6 · standardAP
2020-11-12Labeling · Supplement 17 · standardAP
2020-11-12Labeling · Supplement 11 · standardAP
2018-05-25Manufacturing (CMC) · Supplement 7AP
2014-11-14Labeling · Supplement 3 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.